In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

The selected stress testing protocol is independently associated with mortality irrespective of exercise capacity and comorbidities.

Session Poster Session 2

Speaker Serge Harb

Event : ESC Congress 2019

  • Topic : preventive cardiology
  • Sub-topic : Prevention: Exercise
  • Session type : Poster Session

Authors : S Harb (Cleveland,US), VM Menon (Cleveland,US), YW Wu (Cleveland,US), PC Cremer (Cleveland,US), LC Cho (Cleveland,US), MG Gulati (Phoenix,US), WAJ Jaber (Cleveland,US)

Authors:
S. Harb1 , V.M. Menon1 , Y.W. Wu1 , P.C. Cremer1 , L.C. Cho1 , M.G. Gulati2 , W.A.J. Jaber1 , 1Cleveland Clinic Foundation, Cardiovascular Medicine - Cleveland - United States of America , 2Banner - University Medical Center, Cardiovascular medicine - Phoenix - United States of America ,

Citation:
European Heart Journal ( 2019 ) 40 ( Supplement ), 817

Background: A variety of exercise stress testing protocols with various workloads are available. The test protocol is typically selected according to patient's expected exercise performance.

Purpose: We sought to assess whether the choice of the protocol is by itself independently associated with mortality even after adjusting for clinical variables and estimated workload achieved in metabolic equivalents of task (METS).

Methods: In a 25-year stress testing registry spanning from 1991 to 2015, we identified 120,705 patients who underwent 7 different standardized exercise protocols: Bruce, Modified Bruce, Cornell 0%, 5%, and 10%, Naughton, and modified Naughton. The choice of the protocol was dependent on the supervising exercise physiologist, mainly according to patient's expected exercise performance. The primary outcome was all-cause mortality.

Results: Mean age was 53.3±12.5 years and 59% were male. There were 74953 Bruce, 8368 modified Bruce, 2648 Cornell 0%, 9972 Cornell 5%, 20425 Cornell 10% 1226 Naughton, and 3113 modified Naughton protocols. A total of 8426 death occurred over 8.7 years of mean follow-up duration. Table 1 presents the baseline characteristics by protocol. After adjusting for the number of METs, age, gender, hypertension, diabetes, coronary disease, end-stage renal disease, smoking, and statin use, the protocol selected remained predictive of mortality. Figure 1 shows the adjusted HR for death by protocol selected when compared to Bruce.

Conclusion: The choice of the stress testing protocol, which is in large part dependent on patient's expected exercise performance is in itself independently associated with mortality even after adjustment for METs achieved and patients' demographics and comorbidities. The choice of the modified-Naughton is associated with the greatest risk of mortality, likely chosen based on limited functional capacity

Baseline characteristics by protocol
VariableBruce (n=74953)Modified Bruce (n=8368)Cornell 0% (n=2648)Cornell 5% (n=9972)Cornell 10% (n=20425)Naughton (n=1226)Modified Naughton (n=3113)
Age, mean ± SD49.4±11.361.3±10.366.4±11.762.5±11.857.2±11.567.5±9.855.5±11.9
Male, %64.651.837.842.351.74966.7
Coronary disease, %8.732.531.726.721.149.745.6
Diabetes mellitus, %7.616.525.32014.227.226.2
Hypertension, %41.76485.477.967.182.597.5
Smoker, %40.95550.750.950.856.960.6
ESRD, %0.713.72.41.62.78.1
Mets, mean ± SD10.3±2.47.2±1.75.2±1.66.7±1.58.3±1.94.8±1.54.6±1.5
Statin use, %22.415.241.838.335.11940.1
ESRD = end-stage renal disease; METS = metabolic equivalents of task.
Adjusted HR by protocol selected

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are